Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients

CONCLUSION: A standard nadroparin dosage of 2850 IU sc in the critically ill patient is not sufficient to attain target anti-FXa levels in the majority of the studied patient group. We suggest a standard higher dosage in combination with body-weight dependent dosing as it leads to better exposure to nadroparin.CLINICAL TRIALS REGISTRATION: Retrospectively registered, ClinicalTrials.gov ID NTC 05926518 g, date of registration 06/01/23, unique ID 2020/1725.PMID:38321487 | PMC:PMC10848501 | DOI:10.1186/s40360-024-00733-x

Source: BMC Pharmacology and Toxicology - February 6, 2024 Category: Drugs & Pharmacology Authors: Monique M R de Maat Henk J van Leeuwen Lian Roovers Sabine J G M Ahlers Jolanda Lambers Marcel M C Hovens Source Type: research